Skip to main content

Table 3 Odds ratio (95 % CI) by direct comparison (left lower part) and network meta- analysis (right upper part) based on safety

From: Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis

TwHF

1.21 (0.10–14.26)

0.19 (0.02–2.07)

0.11 (0.01–1.36)

0.66 (0.00–1.64e+28)

0.35 (0.03–3.74)

0.36 (0.04–3.85)

0.32 (0.03–3.19)

MTX

0.16 (0.06–0.40)

0.09 (0.03–0.31)

0.55 (0.00–1.31e+28)

0.29 (0.11–0.73)

0.30 (0.14–0.68)

–

0.74 (0.49–1.10)

LEF

0.58 (0.20–1.66)

3.48 (0.00–8.25e+28)

1.82 (0.93–3.54)

1.92 (1.18–3.13)

0.39 (0.16–1.01)

0.71 (0.40–1.25)

0.93 (0.51–1.36)

SSZ

6.02 (0.00–1.43e+29)

3.15 (1.11–8.91)

3.33 (1.29–8.33)

–

–

2.06 (0.35–12.06)

–

CsA

0.52 (0.00–1.27e+33)

0.55 (0.00–100.0)

–

–

–

–

–

FK506

1.05 (0.67–1.67)

0.37 (0.01–9.98)

0.30 (0.14–0.68)

3.00 (1.87–4.83)

3.32 (1.30–8.45)

–

1.03 (0.65–1.61)

Placebo

  1. Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-defining treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment compared with the row-defining treatment
  2. TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us